Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

How to Qualify Container Closure Systems for Intended Use, Part 1

Author(s):  Kim Amy A, Gehrmann Matthew R, McCaw James, McAndrew T Page

Issue:  Nov/Dec 2019 - Volume 23, Number 6
View All Articles in Issue

Page(s):  454-461

Note:  Electronic version includes errata or revisions.

How to Qualify Container Closure Systems for Intended Use, Part 1 Page 1
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 2
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 3
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 4
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 5
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 6
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 7
How to Qualify Container Closure Systems for Intended Use, Part 1 Page 8

Download in electronic PDF format for $75

Abstract:  The U.S. Food and Drug Administration regulates outsourcing facilities with the same stringency they apply towards drug manufacturers. This means that outsourcing facilities, who must navigate the changing regulatory landscape to achieve and maintain 503B status, need to focus on qualifying container closure systems for their intended use. Container closure systems must be fit-for-purpose (i.e., suitable for in-use conditions relative to drug product stability over intended shelf-life and storage conditions). This article, the first of a two-part series, addresses the critical aspect of how to qualify systems for intended use regarding container closure integrity. The second part will address component selection.

Related Keywords: Amy A. Kim, BS Biology, Matthew R. Gehrmann, BS Chemistry, James McCaw, BS Chemistry, T. Page McAndrew, PhD Chemistry, drug container closures, drug contamination, drug safety regulations, Current Good Manufacturing Practice, CGMP, Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act, 503B status, container closure integrity, fit for purpose, intended use, maximum allowable leak limit, sterile compounding, United States Pharmacopeia <1207> Packaging Integrity Evaluation--Sterile Products, USP, vial systems, stopper systems, seal systems, helium leak method, oxygen headspace method, residual seal force method, compression, microbial contaminants, drug contamination

Related Categories: LEGAL, PACKAGING, STERILE PREPARATIONS, QUALITY CONTROL, STORAGE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
How to Qualify Container Closure Systems for Intended Use, Part 1
Kim Amy A
, Gehrmann Matthew R, McCaw James, McAndrew T Page
Nov/Dec 2019
Pg. 454-461

How to Qualify Container Closure Systems for Intended Use, Part 2: Choosing the Right Components for Container Closure Systems
Vaughn Stacey R
, Radwick Allison
Jan/Feb 2020
Pg. 14-19

Basics of Sterile Compounding: Intravenous Admixture Preparation Considerations, Part 10: Packaging and Container-closure Issues
Allen Loyd V Jr
Jul/Aug 2021
Pg. 311-317

Does Your Drug Expertise Include Clinical Pharmaceutics?
Newton David W
May/Jun 2016
Pg. 202-206

Basics of Compounding for Hazardous Drugs, Part 2: Regulation and Sources of Contamination
Allen Loyd V Jr
Nov/Dec 2006
Pg. 446-448

Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Dillon L R
Jan/Feb 2020
Pg. 30-36

A Review of Parenteral Admixtures Requiring Select Containers and Administration Sets
Rice Stephen P
Mar/Apr 2002
Pg. 120-122

The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists
Parks Kenneth Chase
, Bernard Brian, Cogdill Christopher Blake
Sep/Oct 2015
Pg. 377-380

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Documentation: Records and Reports
Akers Michael J
Sep/Oct 2017
Pg. 373-380

Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms
Akers Michael J
Jan/Feb 2017
Pg. 47-56

Quality Control: How to Produce a Well-closed Sealed Vial in a Regulated CGMP Environment: Part 2
Higgins Doral (Neal) O
, Prudom Melanie J, Summers Amy
Sep/Oct 2021
Pg. 389-395

Errata - How to Qualify Container Closure Systems for Intended Use, Part 1 - IJPC 23(6) 454-461
Jan/Feb 2020
Pg. 86-87

View Sample
Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety
Allen W Chris
, Greeson Nicole MH, Mixon William
Nov/Dec 2020
Pg. 451-458

PostScription: Drug Disposal: Compounding Pharmacists' Involvement in the Prevention of Prescription Drug Misuse and Abuse
Williams LaVonn A
Nov/Dec 2011
Pg. 526-527

Drug Shortage Compounding: The Only Safe Medication Source in a Time of Crisis
Lyon Joanna
Nov/Dec 2012
Pg. 456-460

Quality Control: How to Produce a Well-closed Sealed Vial in a Regulated CGMP Environment: Part 1
Higgins Doral (Neal) O
, Prudom Melanie J, Summers Amy
Jul/Aug 2021
Pg. 298-302

Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Cabaleiro Joe
Sep/Oct 2021
Pg. 358-362

Extending Practical (In Use) Shelf Life of Oncology Drug Vials Using Spikes
de Wilde Sofieke
, Crul Mirjam, Breukels Oscar
Mar/Apr 2023
Pg. 154-159

Transdermals: The Skin as Part of a Drug Delivery System
Allen Loyd V Jr
Jul/Aug 2011
Pg. 308-315

Return to Top